- Stocks
- Pharma & Healthcare
- Vanta Bioscienc
Vanta Bioscienc share price
NSE: VANTABIOPharma & HealthcareDiagnostics & Research
Vanta Bioscienc at a glance
With a market capitalisation of ₹17 Cr, it ranks 3674th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was 0.5% in FY26. Promoters held 72.81% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹17 CrRank 3674 on NSE
- Price to book
- 0.51×FY26
- ROE
- 0.5%FY26
- ROCE
- 1.5%FY26
- Debt to equity
- 1.8FY26
- Net profit margin
- 6.0%FY26
- Book value / share
- ₹29.77FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Vanta Bioscienc financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹10 Cr | ₹10 Cr | ₹6 Cr | ₹10 Cr | ₹2 Cr | — |
| Operating profit | ₹1 Cr | ₹0 Cr | −₹10 Cr | −₹9 Cr | −₹13 Cr | — |
| Net profit | ₹0 Cr | ₹0 Cr | −₹10 Cr | −₹9 Cr | −₹13 Cr | — |
| EPS (₹) | ₹0.00 | ₹0.00 | −₹10.00 | −₹4.00 | −₹8.00 | — |
| Cash from operations | −₹38 Cr | ₹5 Cr | −₹1 Cr | ₹3 Cr | −₹2 Cr | — |
| Total debt | ₹28 Cr | ₹37 Cr | ₹47 Cr | ₹49 Cr | ₹54 Cr | ₹31 Cr |
| Shareholders' equity | ₹24 Cr | ₹24 Cr | ₹18 Cr | ₹15 Cr | ₹10 Cr | ₹21 Cr |
Vanta Bioscienc shareholding pattern
| Holder | 31 Mar 2024 | 30 Sep 2024 | 31 Mar 2025 | 21 Sep 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.36% | 69.36% | 69.36% | 72.81% | 72.81% | 72.81% |
| Non-institutions | 30.64% | 30.64% | 30.64% | 27.19% | 27.19% | 27.19% |
Vanta Bioscienc vs peers
The listed Pharma & Healthcare companies nearest to Vanta Bioscienc by market capitalisation.
Ask anything about Vanta Bioscienc
Pivot answers on the live chart with evidence you can check, and tests strategies against VANTABIO's own history. Try: “Why has VANTABIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on VANTABIO over five years” · “Compare VANTABIO with DESHRAK on margins and valuation”
Frequently asked questions about Vanta Bioscienc
What is the market cap of Vanta Bioscienc?
Vanta Bioscienc's market capitalisation is ₹17 Cr (₹17 Cr) at the 22 Oct 2026 close, ranking 3674th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Vanta Bioscienc?
Return on equity was 0.5% in FY26 and return on capital employed was 1.5% in FY26 (consolidated figures).
Is Vanta Bioscienc a debt-free company?
No. Vanta Bioscienc's debt-to-equity ratio was 1.8 in FY26, with total debt of ₹31 Cr.
What is the shareholding pattern of Vanta Bioscienc?
As of 31 Mar 2026: promoters 72.81%, non-institutions 27.19%.
Who are Vanta Bioscienc's competitors?
The listed Pharma & Healthcare companies closest to Vanta Bioscienc by market cap are Desh Rakshak, Nidan Lab, Venmax Drugs, Zenith Health, Family Care Hos and Colinz Labs.
Is Vanta Bioscienc a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vanta Bioscienc's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VANTABIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text